EviCore’s updated coverage guidelines support access to AI-enabled Plaque Analysis to help physicians precisely diagnose and manage patients with coronary artery diseaseMOUNTAIN VIEW, Calif., July 11, ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive ...

Researchers from The University of Western Australia, working with medtech industry partners Artrya, have developed a new, ...

One in three adults in the U.S. has three or more risk factors for a newly recognized but increasingly common condition: ...

In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, ...

Trends point to more and more PCIs being performed via the wrist, but the US still trails behind other countries.

New 10-year data from the DANAMI-3-PRIMULTI trial show long-term benefits of complete revascularization for patients with ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Background Identifying significant coronary artery disease (CAD) in patients with reduced left ventricular ejection fraction (rLVEF) is essential for guiding therapeutic decisions, including medical ...